access

News

New drugs 'benefit patients, but maybe not populations'

The money spent by the NHS on newly approved therapies recommended by NICE might have been better spent elsewhere, according to a new study.

News

Dr Sam Roberts, NICE chief executive, said AstraZeneca and Daiichi Sankyo had not offered a fair price

NICE blames companies for breakdown in Enhertu talks

Discussions aimed at making AstraZeneca and Daiichi Sankyo's Enhertu available to breast cancer patients on the NHS have been abandoned, according to cost-effectiveness assessor NICE.

R&D

The 5th Operationalize Expanded Access Programs banners

Partner Content

Returning... The 5th Operationalize Expanded Access Programs...

Welcome to, or welcome back to, the 5th Operationalize: Expanded Access Programs Summit 2025!

News

Joy as NICE lifts restrictions on myeloma drug Elrexfio

Patients in England and Wales with multiple myeloma are celebrating a decision by NICE to relax strict restrictions on eligibility to receive Pfizer's Elrexfio.

Patients